Mark P Connolly (Mark Connolly)

ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 37

Top Venues

Expert review of pharmacoeconomics & outcomes research

Vaccines

Oncology and therapy

Postgraduate medicine

University of Groningen

University of Groningen (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Groningen

Netherlands

guest researcher :: Pharmacoeconomics

Global Market Access Solutions

Switzerland

managing director, researcher :: Health Economics

Education History

University of Groningen Mar 01 2008 - Jun 01 2011

Netherlands

PHD :: Health Economics

University of Michigan

United States

MSC :: Pharmacology

Publications

Nikos Kotsopoulos, André Bento-Abreu, Goran Bencina, Mark P Connolly
Fiscal analysis of the pediatric immunization program in Belgium applying a lifetime government perspective framework. Expert review of pharmacoeconomics & outcomes research 24 (3) (2024)
Nikos Kotsopoulos, André Bento-Abreu, Goran Bencina, Mark P Connolly
Fiscal analysis of the pediatric immunization program in Belgium applying a lifetime government perspective framework. Expert review of pharmacoeconomics & outcomes research (2024)
Svenn Alexander Kommandantvold, Nikos Kotsopoulos, Isabel Monteiro, Ana Ladeiras, Andrew Hogan, Felipe Barboza Magalhães de Araujo, Mark P Connolly
Estimating Public Economic Gains from Early Breast Cancer and Curative Treatment: A Case Study in Human Epidermal Growth Factor Receptor (HER-2) Positive Targeted Therapies. Oncology and therapy (2024)
Svenn Alexander Kommandantvold, Nikos Kotsopoulos, Isabel Monteiro, Ana Ladeiras, Andrew Hogan, Felipe Barboza Magalhães de Araujo, Mark P Connolly
Estimating Public Economic Gains from Early Breast Cancer and Curative Treatment: A Case Study in Human Epidermal Growth Factor Receptor (HER-2) Positive Targeted Therapies. Oncology and therapy 12 (2) (2024)
Nikos Kotsopoulos, André Bento-Abreu, Goran Bencina, Mark P Connolly
Fiscal analysis of the Pediatric Immunization Program in Belgium applying a lifetime government perspective framework. Expert review of pharmacoeconomics & outcomes research (2024)
Christopher J De Jonge, Christopher L R Barratt, Robert John Aitken, Richard A Anderson, Peter Baker, David Yiu Leung Chan, Mark P Connolly, Michael L Eisenberg, Nicolas Garrido, Niels Jørgensen, Sarah Kimmins, Csilla Krausz, Robert I McLachlan, Craig Niederberger, Brendan J Houston, Allan A Pacey, Laerke Priskorn, Satu Rautakallio-Hokkanen, Gamal Serour, Joris A Veltman, Donna L Vogel, Mónica Hebe Vazquez-Levin
Current global status of male reproductive health. Human reproduction open 2024 (2) (2024)
Svenn Alexander Kommandantvold, Nikos Kotsopoulos, Isabel Monteiro, Ana Ladeiras, Andrew Hogan, Felipe Barboza Magalhães de Araujo, Mark P Connolly
Estimating Public Economic Gains from Early Breast Cancer and Curative Treatment: A Case Study in Human Epidermal Growth Factor Receptor (HER-2) Positive Targeted Therapies. Oncology and therapy 12 (2) (2024)
Christopher J De Jonge, Christopher L R Barratt, Robert John Aitken, Richard A Anderson, Peter Baker, David Yiu Leung Chan, Mark P Connolly, Michael L Eisenberg, Nicolas Garrido, Niels Jørgensen, Sarah Kimmins, Csilla Krausz, Robert I McLachlan, Craig Niederberger, Brendan J Houston, Allan A Pacey, Laerke Priskorn, Satu Rautakallio-Hokkanen, Gamal Serour, Joris A Veltman, Donna L Vogel, Mónica Hebe Vazquez-Levin
Current global status of male reproductive health. Human reproduction open 2024 (2) (2024)
Svenn Alexander Kommandantvold, Nikos Kotsopoulos, Isabel Monteiro, Ana Ladeiras, Andrew Hogan, Felipe Barboza Magalhães de Araujo, Mark P Connolly
Estimating Public Economic Gains from Early Breast Cancer and Curative Treatment: A Case Study in Human Epidermal Growth Factor Receptor (HER-2) Positive Targeted Therapies. Oncology and therapy 12 (2) (2024)
Nikos Kotsopoulos, André Bento-Abreu, Goran Bencina, Mark P Connolly
Fiscal analysis of the pediatric immunization program in Belgium applying a lifetime government perspective framework. Expert review of pharmacoeconomics & outcomes research 24 (3) (2024)
Simon van der Schans, Marcel H Schöttler, Jurjen van der Schans, Mark P Connolly, Maarten J Postma, Cornelis Boersma
Investing in the Prevention of Communicable Disease Outbreaks: Fiscal Health Modelling-The Tool of Choice for Assessing Public Finance Sustainability. Vaccines 11 (4) (2023)
Simon van der Schans, Marcel H Schöttler, Jurjen van der Schans, Mark P Connolly, Maarten J Postma, Cornelis Boersma
Investing in the Prevention of Communicable Disease Outbreaks: Fiscal Health Modelling-The Tool of Choice for Assessing Public Finance Sustainability. Vaccines 11 (4) (2023)
Simon van der Schans, Marcel H Schöttler, Jurjen van der Schans, Mark P Connolly, Maarten J Postma, Cornelis Boersma
Investing in the Prevention of Communicable Disease Outbreaks: Fiscal Health Modelling-The Tool of Choice for Assessing Public Finance Sustainability. Vaccines 11 (4) (2023)
Simon van der Schans, Marcel H Schöttler, Jurjen van der Schans, Mark P Connolly, Maarten J Postma, Cornelis Boersma
Investing in the Prevention of Communicable Disease Outbreaks: Fiscal Health Modelling-The Tool of Choice for Assessing Public Finance Sustainability. Vaccines 11 (4) (2023)
Mark P Connolly, Nikolaos Kotsopoulos, Craig Roberts, Laurence Kotlikoff, David E Bloom, Tianyan Hu, Mawuli Nyaku
Public economic gains from tax-financed investments in childhood immunization in the United States. PLOS global public health 3 (10) (2023)
Nikolaos Kotsopoulos, Mark P Connolly
Assessing the Fiscal Burden of Obesity in Canada by Applying a Public Economic Framework. Advances in therapy (2023)
Ana Teresa Paquete, Rui Martins, Mark P Connolly, Marie Meulle, Nítida Pastor, Grégoire Benoist, Patrick Tounian
Cost-effectiveness of infant hypoallergenic formulas to manage cow's milk protein allergy in France. Journal of market access & health policy 11 (1) (2022)
Nikolaos Kotsopoulos, Mark P Connolly, Michael Willis, Andreas Nilsson, Åsa Ericsson, James Baker-Knight
The public economic burden of suboptimal type 2 diabetes control upon taxpayers in Sweden: Looking beyond health costs. Diabetes, obesity & metabolism 24 (6) (2022)
Ana Teresa Paquete, Rui Martins, Mark P Connolly, Marie Meulle, Nítida Pastor, Grégoire Benoist, Patrick Tounian
Cost-effectiveness of infant hypoallergenic formulas to manage cow's milk protein allergy in France. Journal of market access & health policy 11 (1) (2022)
Mark P Connolly, Nikos Kotsopoulos, Sebastian Vermeersch, Julien Patris, David Cassiman
Estimating the broader fiscal consequences of acute hepatic porphyria (AHP) with recurrent attacks in Belgium using a public economic analytic framework. Orphanet journal of rare diseases 16 (1) (2021)
Goran Medic, Nikos Kotsopoulos, Mark P Connolly, Jennifer Lavelle, Vincent Norlock, Manish Wadhwa, Belinda A Mohr, Wayne M Derkac
Mobile Cardiac Outpatient Telemetry Patch vs Implantable Loop Recorder in Cryptogenic Stroke Patients in the US - Cost-Minimization Model. Medical devices (Auckland, N.Z.) 14 (2021)
Nikolaos Kotsopoulos, Mark P Connolly, Jinjing Li
Estimating the public economic consequences of cardiovascular disease-attributable events and evolocumab treatment in Australia. Journal of medical economics 24 (1) (2021)
Nikolaos Kotsopoulos, Mark P Connolly, Thibaut Dort, Andrius Kavaliunas
The fiscal consequences of public health investments in disease-modifying therapies for the treatment of multiple sclerosis in Sweden. Journal of medical economics 23 (8) (2020)
Mark P Connolly, Nikolaos Kotsopoulos, Aomesh Bhatt, Maarten J Postma
Sustainability of public finances: inclusion of unrelated medical cost only part of the story. The European journal of health economics : HEPAC : health economics in prevention and care 20 (8) (2020)
Mark P Connolly, Nikolaos Kotsopoulos
Estimating the Fiscal Consequences of National Immunization Programs Using a "Government Perspective" Public Economic Framework. Vaccines 8 (3) (2020)
Baudouin Standaert, Christophe Sauboin, Quentin J Leclerc, Mark P Connolly
Comparing the Analysis and Results of a Modified Social Accounting Matrix Framework with Conventional Methods of Reporting Indirect Non-Medical Costs. PharmacoEconomics 39 (2) (2020)
Saswat Panda, Mark P Connolly, Manuel G Ramirez, Juan Beltrán de Heredia
Costs Analysis of Fibrin Sealant for Prevention of Anastomotic Leakage in Lower Colorectal Surgery. Risk management and healthcare policy 13 (2020)
Mark P Connolly, Saswat Panda, Julien Patris, Bouke P C Hazenberg
Estimating the fiscal impact of rare diseases using a public economic framework: a case study applied to hereditary transthyretin-mediated (hATTR) amyloidosis. Orphanet journal of rare diseases 14 (1) (2019)
Mark P Connolly, Nikolaos Kotsopoulos, Aomesh Bhatt, Maarten J Postma
Sustainability of public finances: inclusion of unrelated medical cost only part of the story. The European journal of health economics : HEPAC : health economics in prevention and care (2019)
Ruben R Ben-Harari, Mark P Connolly
High burden and low awareness of toxoplasmosis in the United States. Postgraduate medicine 131 (2) (2019)
Mark P Connolly, Saswat Panda, Ha Young Kim
Estimating the Fiscal Costs of Osteoporosis in Korea Applying a Public Economic Perspective. Journal of bone metabolism 26 (4) (2019)
Nikolaos Kotsopoulos, Gertruud Haitsma, Mark P Connolly, Baudouin Standaert
Estimating the money flow in the economy attributed to rotavirus disease and vaccination in the Netherlands using a Social Accounting Matrix (SAM) framework. Expert review of pharmacoeconomics & outcomes research 20 (6) (2019)
Manisha Maganji, Mark P Connolly, Aomesh Bhatt
Cutaneous irritancy of an ibuprofen medicated plaster in healthy volunteers. Postgraduate medicine 130 (3) (2018)
Mark P Connolly, Nikolaos Kotsopoulos, Pichaya Suthipinijtham, Suthat Rungruanghiranya
Fiscal Impact of Smoking Cessation in Thailand: A Government Perspective Cost-Benefit Analysis. Asia-Pacific journal of public health 30 (4) (2018)
Saswat Panda, Mark P Connolly, Manuel G Ramirez
Cost comparison of fibrin sealant versus tack screws for mesh fixation in laparoscopic repair of inguinal hernia. Hospital practice (1995) 46 (4) (2018)
Kathy Belk, Mark P Connolly, Lisa Schlesinger, Ruben R Ben-Harari
Patient and treatment pathways for toxoplasmosis in the United States: data analysis of the Vizient Health Systems Data from 2011 to 2017. Pathogens and global health 112 (8) (2018)
Hans-Georg Predel, Bruno Giannetti, Mark P Connolly, Fraser Lewis, Aomesh Bhatt
Efficacy and tolerability of a new ibuprofen 200mg plaster in patients with acute sports-related traumatic blunt soft tissue injury/contusion. Postgraduate medicine 130 (1) (2017)

Mark P Connolly.css-eqlu8i{font-size:small;padding-left:4px;} (Mark Connolly)

Publication Activity (10 Years)

Top Topics

Top Venues

Mark P Connolly (Mark Connolly)